Clinical Trial Update: A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial investigating C-CAR168 for autoimmune diseases refractory to standard therapy is currently recruiting, covering SLE, IMNM, NMOSD, MS, Mya…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune-mediated Necrotizing Myopathy
• Multiple Sclerosis
• Myasthenia Gravis
• Neuromyelitis Optica Spectrum Disorders
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• C-CAR168

Snippet

Sponsor: RenJi Hospital | Conditions: Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM) | Phase 1 | Status: RECRUITING